Publication: Therapeutic neovascularization for peripheral arterial diseases: advances and perspectives
Loading...
Date
2007
Authors
Zhou, B. ; Poon, M-C. ; Pu, W.T. ; Han, Z.C.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Recently, with the better understanding of the
mechanisms of neovascularization, many new
therapeutic approaches to enhance neovascularization
have emerged. Of these diverse emerging methods, use
of growth factors and cells are the two major ones. This
review will provide an update on the present
understanding of the basic mechanisms of angiogenesis,
vasculogenesis, and arteriogenesis, as a basis for
designing future pro-neovascularization treatments.
Several angiogenic factors including vascular
endothelial growth factor (VEGF) and fibroblast growth
factor (FGF) have been implicated in augmenting the
neovascularization process. However, single growth
factors are not sufficient to generate functional vessels.
In synergistic or complementary manner, these factors
may be used in harmony to form long-term functional
vessels. Cell therapy has the potential to supply
stem/progenitor cells and multiple angiogenic factors to
the region of ischemia. However, the efficacy of stem
cells transplantation may be impaired by low survival
rate, insufficient cell number and impaired function in
aging and diseases. Combination of cells or cells primed
with growth factor(s) or genetic modification may
augment the therapeutic efficacy. This paper reviews
critical literature in depth to elucidate the mechanism of
therapeutic neovascularization, angiogenic factor
therapy and cell transplantation. Based on past
experience and actual knowledge, we propose future problems and controversies that need to be addressed in
order to fully exploit the potential of growth factors
and/or cell transplantation with clinical relevance.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.